Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | PTGES | O14684 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.51 |
| ▸ | LOX | P28300 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79534 | 0.83 | ALOX5 (0.54) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL16399862 | 0.80 | ALOX5 (0.55) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL2161082 | 0.80 | ALOX5 (0.51) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL28657389 | 0.80 | ALOX5 (0.55) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL139543 | 0.80 | ALOX5 (0.55) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL1444769 | 0.80 | ALOX5 (0.55) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL4361286 | 0.80 | ALOX5 (0.51) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL30238692 | 0.80 | ALOX5 (0.55) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL24119344 | 0.77 | ALOX5 (0.49) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL13619726 | 0.77 | ALOX5 (0.49) | ALOX5CYP1A2PTGESLMNALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126987-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-09-08 | — | — | US | disclosed |
| EP-2091948-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-04-18 | — | — | EP | disclosed |
| EP-2091948-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-20080214620-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008065141-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214620-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, GLUL | ALOX5 2710/4885CYP1A2 3053/4885PTGES 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.